Comparative Pharmacology
Head-to-head clinical analysis: GLATOPA versus REBIF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLATOPA versus REBIF.
GLATOPA vs REBIF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glatiramer acetate (GLATOPA) is a mixture of synthetic polypeptides that alters immune processes by inducing and expanding T-helper 2 (Th2) regulatory cells, which suppress pro-inflammatory T-helper 1 (Th1) cells. It also competes with myelin basic protein for binding to major histocompatibility complex (MHC) molecules, thereby modulating antigen presentation and reducing autoimmune attack on myelin.
Interferon beta-1a binds to type I interferon receptors, activating the JAK-STAT signaling pathway, which leads to expression of interferon-responsive genes. This results in modulation of immune responses, including reduction of pro-inflammatory cytokines, enhancement of anti-inflammatory cytokines, inhibition of T-cell activation and proliferation, and decreased blood-brain barrier permeability.
20 mg subcutaneously once daily.
Subcutaneous injection, 22 mcg (0.5 mL) or 44 mcg (0.5 mL) three times per week, at least 48 hours apart.
None Documented
None Documented
The terminal elimination half-life of glatiramer is approximately 1.5–2 hours after subcutaneous administration. This short half-life is due to rapid proteolytic degradation; however, the clinical effect persists for days due to immunological mechanisms.
Terminal half-life approximately 50 hours (range 28-75 hours) after subcutaneous administration, supporting every-other-day dosing.
Glatiramer acetate is extensively metabolized locally at the injection site and systemically by proteolysis. The metabolites are eliminated primarily via renal excretion (approximately 70%) and biliary/fecal excretion (approximately 30%). Less than 1% is excreted unchanged.
Renal (primarily via glomerular filtration and catabolism) and hepatic metabolism; <5% excreted unchanged in urine.
Category C
Category C
Immunomodulator
Immunomodulator